3 research outputs found
Consensus-based care recommendations for adults with myotonic dystrophy type 1
Purpose of review
Myotonic dystrophy type 1 (DM1) is a severe, progressive genetic disease that affects between 1 in 3,000 and 8,000 individuals globally. No evidence-based guideline exists to inform the care of these patients, and most do not have access to multidisciplinary care centers staffed by experienced professionals, creating a clinical care deficit.
Recent findings
The Myotonic Dystrophy Foundation (MDF) recruited 66 international clinicians experienced in DM1 patient care to develop consensus-based care recommendations. MDF created a 2-step methodology for the project using elements of the Single Text Procedure and the Nominal Group Technique. The process generated a 4-page Quick Reference Guide and a comprehensive, 55-page document that provides clinical
care recommendations for 19 discrete body systems and/or care considerations.
Summary
The resulting recommendations are intended to help standardize and elevate care for this patient population and reduce variability in clinical trial and study environments. Described as “one of the more variable diseases found in medicine,” myotonic dystrophy type
1 (DM1) is an autosomal dominant, triplet-repeat expansion disorder that affects somewhere between 1:3,000 and 1:8,000 individuals worldwide.1 There is a modest association between increased repeat expansion and disease severity, as evidenced by the average age of onset and overall morbidity of the condition. An expansion of over 35 repeats typically indicates an unstable and expanding mutation. An expansion of 50 repeats or higher is consistent with a diagnosis of DM1. DM1 is a multisystem and heterogeneous disease characterized by distal weakness, atrophy, and myotonia, as well as symptoms in the heart, brain, gastrointestinal tract, endocrine, and respiratory systems. Symptoms may occur at any age. The severity of the condition varies widely among affected individuals, even among members of the same family.
Comprehensive evidence-based guidelines do not currently
exist to guide the treatment of DM1 patients. As a result, the international patient community reports varied levels of care and care quality, and difficulty accessing care adequate to manage their symptoms, unless they have access to multidisciplinary neuromuscular clinics.
Consensus-based care recommendations can help standardize
and improve the quality of care received by DM1 patients
and assist clinicians who may not be familiar with the significant variability, range of symptoms, and severity of the disease. Care recommendations can also improve the landscape for clinical trial success by eliminating some of the inconsistencies in patient care to allow more accurate understanding of the benefit of potential therapies
Recommended from our members
How many polysomnograms must sleep fellows score before becoming proficient at scoring sleep?
In the field of sleep medicine, there is a paucity of evidence-based curriculum development strategies in the literature. We chose to determine the number of polysomnograms (PSG) necessary to be scored by sleep fellows in order to reasonably approximate sleep scoring by a Diplomate of the American Board of Sleep Medicine (DABSM).
The fifth PSG scored by two sleep fellows during the 12 consecutive months of training was chosen for analysis. A DABSM not involved in the training of fellows scored sleep on each of the selected PSG with replication of montage and filter settings. Epoch by epoch comparison of sleep stage scoring is described as the frequency of concordance between fellow and DABSM (f correct).
The mean (SD) f correct for all PSG for each fellow was 0.83 (0.06) and 0.83 (0.08) (p = 0.93). Concordance between sleep fellow and DABSM approached 0.8 after scoring between 20-30 PSG. This milestone was reached after the fourth month of training. F correct was highest for stage 2 sleep and REM sleep and most variable for slow wave sleep and stage 1 sleep. The variability in f correct for these stages was in part related to the relative paucity of these sleep stages.
Scoring of sleep becomes reasonably proficient after scoring approximately 20-30 PSG and/or four months of dedicated sleep disorders training. A standard measure of concordance that corrects for epoch sample size may be helpful for use in future similar investigations
Consensus-based care recommendations for adults with myotonic dystrophy type 1
International audiencePurpose of review Myotonic dystrophy type 1 (DM1) is a severe, progressive genetic disease that affects between 1 in 3,000 and 8,000 individuals globally. No evidence-based guideline exists to inform the care of these patients, and most do not have access to multidisciplinary care centers staffed by experienced professionals, creating a clinical care deficit. Recent findings The Myotonic Dystrophy Foundation (MDF) recruited 66 international clinicians experienced in DM1 patient care to develop consensus-based care recommendations. MDF created a 2-step methodology for the project using elements of the Single Text Procedure and the Nominal Group Technique. The process generated a 4-page Quick Reference Guide and a comprehensive, 55-page document that provides clinical care recommendations for 19 discrete body systems and/or care considerations. Summary The resulting recommendations are intended to help standardize and elevate care for this patient population and reduce variability in clinical trial and study environments